

# CUMULATIVE INDEX 1999

## Volume 25

February	PAIN MANAGEMENT IN RHEUMATIC DISEASE, pages 1-256
May	OSTEOARTHRITIS, pages 257-488
August	GENERAL MEDICAL CARE OF THE PATIENT WITH RHEUMATIC DISEASE, pages 489-788
November	COMPLEMENTARY AND ALTERNATIVE THERAPIES FOR RHEUMATIC DISEASE, PART I, pages 789-994

Note: Page numbers of article titles are in **boldface** type

- Abdominal pain, in dyspepsia, 703
- Acarbose, in diabetes mellitus, corticosteroid-related, 494-496
- Acetaminophen, 168-170
  - analgesic action of, 202
  - in juvenile rheumatoid arthritis, 37
  - in osteoarthritis, 154-155, 178
- Acupuncture, as form of complementary and alternative medicine, 837-838
- Addiction, to opioids, 198-200
- Adjustment disorder with depressed mood, 699-700
- $\alpha$ -2-Adrenergic agents, in pain management, 205
- Aerobic exercise, in pain management, 242-243
- Affect, pain and, 82-84, **105-121**
  - anger, 108-109
  - anxiety, 108
  - depression, 108
  - dimensions of, 105-107
  - functional imaging studies of, 138-141
  - mechanisms for, 110-114
    - physiologic, 110-112
    - psychological, 112-114
  - research needs on, 144-146
  - review of, 106-110
  - treatment implications of, 116-117
- Age, chronic pain susceptibility and, 61-62
- Aggrecan, as cartilage damage and repair marker, 419-421, 435, 442
- Aggrecan/COMP ratio, as cartilage damage and repair marker, 437-438
- Aggrecanase, as cartilage damage and repair marker, 435
- Aging, knee proprioception changes with, 306
  - osteoarthritis in, muscle weakness and, 288
- AIMS (Arthritis Impact Measurement Scale), 96-97
- Albumin, radiolabeled (RISA), in synovial space measurement, 439-441, 443-444
- Alkaline phosphatase, in crystal-associated osteoarthritis, 263-264
- Allen test, in peripheral arterial disease, 673
- Allopurinol, nephrotoxicity of, 762
  - pharmacokinetics of, 763
- Alpha-2-adrenergic agents, in pain management, 205
- Alpha-tocopherol, osteoarthritis and, 323-325
- Alzheimer's disease, cyclooxygenase-2 in, 364
- American College of Cardiology/American Heart Association guidelines, for cardiovascular management in non-cardiac surgery, 600-607
- American College of Physicians guidelines, for cardiovascular management in non-cardiac surgery, 600-601, 605-606
- American College of Rheumatology, 830
- American College of Sports Medicine, exercise recommendations of, 399-400
- American Heart Association guidelines, for cardiovascular management in non-cardiac surgery, 600-607
  - for endocarditis prophylaxis, 628-631

- American Society of Anesthesiologists, risk stratification classification of, 586
- Amitriptyline, in depression, 697
- in pain management, 174-175, 203
- in fibromyalgia, 27
- Amputation, in peripheral arterial disease, 670
- Amygdala, in pain perception, 140-141
- Analgesia, 153-191. See also  
*Acetaminophen*; *Nonsteroidal anti-inflammatory drugs*; *Opioids*.  
 antidepressants in, 27, 173-175, 202-203  
 approach to, 175-179  
 in acute pain, 176-177  
 in chronic pain, 177-179  
 counterirritants, 175, 206, 237  
 for needle procedures, in pediatric patients, 48-49  
 mechanisms of, 195  
 muscle relaxants in, 171-173, 177, 205-206  
 topical, 175, 206, 236-237
- Androgens, in menopause, 560
- Anemia, preoperative considerations in, 609, 612
- Anger, pain in, 108-109
- Angiography, in peripheral arterial disease, 676
- Angioplasty, coronary, in coronary artery disease, 666  
 preoperative, 594-595  
 in peripheral arterial disease, 680, 682-683
- Angiotensin-converting enzyme inhibitors, in hypertension, in asthma, 529  
 in diabetes mellitus, 526  
 in kidney dysfunction, 530
- Angiotensin II receptor blockers, in hypertension, in asthma, 529
- Ankle, exercise for, in knee osteoarthritis, 401-402
- Ankle/brachial index, in peripheral arterial disease, 674-675
- Ankylosing spondylitis, pain in, 22-23  
 spa therapy for, 889-891
- Ant venom, in rheumatoid arthritis, 925
- Antacids, in heartburn, 711
- Anthrax vaccination, in immunodeficiency, 579
- Antibiotics, and immune or inflammatory mechanisms in pathogenesis of rheumatic disease, 875-877  
 for treatment of rheumatic disease, 861-881  
 functions of, in modification of human inflammation, 862-863
- Anticoagulants. See also *Heparin*; *Warfarin*.  
 discontinuation of, preoperative, 598
- Antidepressants, in depression, 694-697  
 in pain management, 27, 173-175, 202-203
- Antiepileptic drugs, in pain management, 203-204
- Antihyperglycemic agents, in diabetes mellitus, corticosteroid-related, 494-497
- Anti-inflammatory drugs, nonsteroidal.  
 See *Nonsteroidal anti-inflammatory drugs*.
- Antioxidant nutrients, in rheumatic disease, 957-958
- Antioxidant vitamins, osteoarthritis and, mechanisms of, 316-318  
 vitamin A, 318-321  
 vitamin C, 321-323  
 vitamin E, 323-325
- Antiphospholipid antibody syndrome, oral contraceptives in, 541  
 pregnancy in, 549-550  
 thromboembolism in, postoperative, 633
- Antiplatelet agents, in peripheral arterial disease, 678
- Antireflux surgery, in heartburn, 711
- Anxiety, pain and, 108, 216-217
- Aortic regurgitation, preoperative risks in, 598
- Aortic stenosis, preoperative risks in, 597-598
- Aortoiliac occlusive disease, treatment of, 680
- Apatite crystals, carbonate-substituted. See *Calcium-containing crystals*.
- Apolipoproteins, 508
- Apoptosis, of chondrocytes, in osteoarthritis, 273, 334
- Arachidonic acid metabolites. See also *Prostaglandin(s)*.  
 in osteoarthritis, 317-318
- Arrhythmias, cardiac, preoperative risks in, 599-600
- Arterial occlusive disease. See *Peripheral arterial disease*.
- Arteriography, in peripheral arterial disease, 676
- Arteritis, Takayasu's, versus peripheral arterial disease, 672, 676
- Arthritis, crystal-induced, after joint replacement, 634  
 degenerative. See *Osteoarthritis*.  
 Lyme, antibiotic-refractory, 873  
 measles-mumps-rubella vaccine associated with, 576  
 psoriatic, lipid disorders in, 514  
 spa therapy for, 891  
 reactive, in influenza vaccination, 577  
 rheumatoid. See *Rheumatoid arthritis*.
- Arthritis Appraisal and Ways of Coping scale, 86
- Arthritis Foundation, 830
- Arthritis Helplessness Index, 88-89
- Arthritis Impact Measurement Scale, 96-97
- "Arthritis personality," 91

- Arthritis Self-Efficacy Scale, 88  
 Arthritis Self-Management Program, 224  
 Arthrocentesis, in osteoarthritis, 19  
 Arthroscopy, in hyaluronic acid injection evaluation, 350  
 Artifacts, in magnetic resonance imaging, in osteoarthritis, 454  
 Ascorbic acid (vitamin C), osteoarthritis and, 321-323  
 Aspirin, in colorectal cancer prevention, 365-366  
   in peripheral arterial disease, 678  
   in pregnancy, 555  
   in thromboembolism prophylaxis, in hip fracture repair, 649  
   in hip replacement, 646-647  
   pharmacokinetics of, 763  
 Asplenia, pneumococcal vaccination in, 570-571  
 Asthma, as surgical risk factor, 608  
   hypertension in, treatment of, 529  
 Atenolol, in coronary artery disease, perioperative, 592  
 Atherosclerosis, in rheumatic disease, coronary artery disease and, 658  
   lipid disorders in. *See Lipid disorders.*  
   large artery occlusive disease in. *See Peripheral arterial disease.*  
 Atorvastatin, in lipid disorders, 516  
 Atrioventricular block, preoperative risks in, 599  
 Attention, in pain perception, 139-140  
 Azathioprine, cancer from, in rheumatoid arthritis, 729-730  
   hepatotoxicity of, 754-755  
   in pregnancy, 554  
   nephrotoxicity of, 762  
   perioperative management of, 628  
   pharmacokinetics of, 763
- Bacille-Calmette-Guerin vaccination, in immunodeficiency, 579  
 Back pain, chronic, spa therapy for, 891-893  
 Baclofen, in pain management, 205  
 Balneotherapy. *See Spa therapy.*  
 Barrier methods, of contraception, 540, 542-543  
 Basic calcium phosphate crystals. *See Calcium-containing crystals.*  
 Bee venoms, biological activity of, 923-924  
   for medicinal purposes, historical review of, 922  
   in rheumatoid arthritis, studies of, 922-923, 924-925  
   peptides and proteins in, 923-924  
 Behavioral factors, in pain, 113-114. *See also Cognitive-behavioral therapy.*
- Benzodiazepines, in pain management, 205-206  
 Beta-blockers, in coronary artery disease, perioperative, 592-593  
   in hypertension, in diabetes mellitus, 528  
   in peripheral arterial disease, 528  
   perioperative, 596  
 Beta-carotene, osteoarthritis and, 318-321  
 Biguanides, in diabetes mellitus, corticosteroid-related, 495-497  
 Bile acid sequestrants, in lipid disorders, 515-517  
 Biopsychosocial model, of pain, 82-83  
 Blood pressure, high. *See Hypertension.*  
   in ankle/brachial index, in peripheral arterial disease, 674-675  
 Bone loss, prostaglandins in, 162  
 Bone marrow, edema of, in osteoarthritis, 461  
 Bone(s), cyclooxygenase-2 in, 365  
   development of, vitamin A in, 321  
   vitamin D in, 328-329  
   magnetic resonance imaging of, in osteoarthritis, 461-463  
 Bowel toxicity, reduction of, in arthritis, 953  
 Braces, knee, proprioception enhancement with, 309-310  
 Brain, cyclooxygenase-2 in, 364-365  
 Breast cancer, screening for, 725-727  
 Bromaline, in rheumatic diseases, 954  
 Bruit, in peripheral arterial disease, 673  
 Bupropion, in depression, 696  
   in pain management, 173-174
- C-reactive protein, after joint replacement, 635  
 Calcium channel blockers, in hypertension, cyclosporine-induced, 532  
   in diabetes mellitus, 527  
   in gastroesophageal reflux disease, 529-530  
   in kidney dysfunction, 531  
   in Raynaud's phenomenon, 529  
 Calcium-containing crystals, in osteoarthritis, 257-267  
   clinical associations of, 258-260  
   cytokine formation from, 262  
   metalloprotease induction by, 261-262  
   mitogenic effects of, 260-261  
   prevention of, 263  
   prostaglandin formation from, 262  
 Calcium pyrophosphate crystal disease, after joint replacement, 634  
 Calcium pyrophosphate dihydrate crystals. *See Calcium-containing crystals.*  
 Calming self-statements, in juvenile rheumatoid arthritis, 46

- Cancer, colorectal, cyclooxygenase-2 in, 365-366  
 gastric, versus dyspepsia, 706-707  
 rheumatic disease with, treatment conflicts in, 764-767  
 risk of, from oral contraceptives, 541  
 screening for, **719-744**  
   breast, 725-727  
   cervical, 724-725  
   colorectal, 720-721  
   in dermatomyositis, 732-734  
   in polymyositis, 732-734  
   in rheumatoid arthritis, 728-732  
   in scleroderma, 734-736  
   in Sjögren's syndrome, 730-731  
   in systemic lupus erythematosus, 736-739  
   prostate, 720-724  
 Cane, in hip pain, 239  
 Capsaicin, 910, 914  
   in pain management, 175, 206, 237  
 Carbamazepine, in pain management, 203-204  
 Cardiac arrhythmias, preoperative risks in, 599-600  
 Cardiac catheterization, in coronary artery disease, 665  
 Cardiovascular disease. *See also* *Coronary artery disease*; *Myocardial infarction*.  
   atherosclerotic. *See* *Lipid disorders*.  
   preoperative considerations in, 588-607  
     arrhythmias, 599-600  
     conduction disturbances, 599-600  
     congestive heart failure, 596-597  
     endocarditis prophylaxis, 628-631  
     hypertension, 595-596  
     in diabetes mellitus, 611  
     ischemia, 591-595  
     management algorithms for, 600-607  
     risk assessment for, 588-591  
     valvular, 597-599  
 Cardiovascular health, exercise for, in osteoarthritis, 404-405, 407-408  
 Carotenoids, osteoarthritis and, 318-321  
   in bone development, 321  
   in cell differentiation, 320  
   in immune response, 320  
   in oxidative stress, 319-320  
 Cartilage, components of, 418  
   degeneration of. *See also* *Osteoarthritis*.  
   serum markers of, **417-432**  
   synovial markers of, **433-449**  
   enhanced synthesis of, in osteoarthritis treatment, 335-336  
   magnetic resonance imaging of, in osteoarthritis, 456, 458-460  
   metabolism of, 419  
 Cartilage matrix protein, as cartilage damage and repair marker, 425-426  
 Cartilage oligomeric matrix protein, as cartilage damage and repair marker, 423-425, 434-437, 442  
 Catheterization, cardiac, in coronary artery disease, 665  
 Ceftriaxone, in rheumatoid arthritis, 870  
 Celecoxib, in arthritis, 162-163  
   in osteoarthritis, 370-371  
 Cellular differentiation, vitamins in, 318  
   vitamin A, 320  
   vitamin D, 328-329  
 Central nervous system, cyclooxygenase-2 in, 364-365  
 Cerebral cortex, in pain-control system, 5  
 Ceruloplasmin, properties of, 930  
 Cervical cancer, screening for, 724-725  
 Cervical spine, instability of, in rheumatoid arthritis, 610  
 Cervistatin, in lipid disorders, 516  
 Charlatans, 805-806, 808  
 Chelation therapy, for peripheral arterial disease, 679  
 Chemotherapy, infertility from, 549  
   rheumatic disease after, 766-767  
 Chiropractic, as form of complementary and alternative medicine, 837, 840  
 Chlorambucil, in pregnancy, 555  
 Chloroquine, in pregnancy, 554  
   pharmacokinetics of, 763  
   psoriasis exacerbation from, 756-757  
 Cholecalciferol (vitamin D), osteoarthritis and, 326-329  
 Cholesterol disorders. *See* *Lipid disorders*.  
 Cholestyramine, in lipid disorders, 516-517  
 Chondrocytes, apoptosis of, in osteoarthritis, 273, 334  
   gene therapy for, in osteoarthritis. *See* *Gene therapy, for osteoarthritis*.  
   inhibition of, NSAIDs in, 161-162  
   metabolism of, in osteoarthritis, 333-335  
   nitric oxide production in, regulation of, 269-272  
   oxygen radical damage of, 317-318  
   proliferation of, nitric oxide effects on, 272-273  
   transplantation of, in osteoarthritis, 336  
 Chondroitin sulfate, as cartilage damage and repair marker, 421, 434-435, 438  
   in osteoarthritis, 387, 389-391  
 Chondroprogenitor cells, as gene therapy targets, for osteoarthritis, 340  
 Chronic fatigue syndrome, diet therapy and, 951  
 Chronic obstructive pulmonary disease, as surgical risk factor, 608  
 Chylomicrons, 508  
 Cilostazol, in peripheral arterial disease, 679  
 Cimetidine, in dyspepsia, 708  
 Cingulate cortex, in pain matrix, 139-140  
 Cirrhosis, liver, drug toxicity in, 750  
 Cisapride, in dyspepsia, 708

- in heartburn, 710
- Citalopram, in depression, 695
- Claudication, intermittent, in peripheral arterial disease, 671
- Clonidine, in menopause, 560
  - in opioid withdrawal, 198
  - in pain management, 205
- Clopidogrel, in peripheral arterial disease, 678-679
- CMP (cartilage matrix protein), as cartilage damage and repair marker, 425-426
- Coagulation disorders, after joint replacement. *See Joint replacement, thromboembolic complications of.*
- in liver disease, 750
- perioperative, from nonsteroidal anti-inflammatory drugs, 623-624
- preoperative considerations in, 609, 612-613
- Codeine, 168-170
- Cognitive-behavioral therapy, 116-117, 220-226
  - coping skills training in, 45-47, 222
  - education in, 221-222
  - for fibromyalgia, 225-226
  - for juvenile rheumatoid arthritis, 43-48
  - coping skills training in, 45-47
  - efficacy of, 47-48
  - rationale for, 44-45
  - for osteoarthritis, 224-225
  - for rheumatoid arthritis, 223-224
  - relapse prevention training in, 222-223
- Cognitive-behavioral variables, in fibromyalgia, 65-68
  - measures for, 97-98
- Cognitive dysfunction, from NSAIDs, 161
- Cognitive Error Questionnaire, 90
- Cognitive factors, in pain, 112-113
  - assessment of, 89-91
  - functional imaging studies of, 138-141
- Colchicine, nephrotoxicity of, 762
  - pharmacokinetics of, 763
- Cold, in pain management, 235-236
- Colestipol, in lipid disorders, 516-517
- Collagen hydrolysate, in osteoarthritis, 390, 392
- Collagen type II, in rheumatic diseases, 954-955
- Collagenases, as cartilage damage and repair markers, 435
  - induction of, in crystal-associated osteoarthritis, 261-262
  - nitric oxide effects on, 275-276
- Collagen(s), as cartilage damage and repair markers, 421-423
  - minor, 426
  - type II, 435, 440
- Colon, nonsteroidal anti-inflammatory drug toxicity to, 747
- Colonoscopy, in colorectal cancer screening, 721
- Colorectal cancer, cyclooxygenase-2 in, 365-366
  - screening for, 720-721
- Commercialism, and quackery, 809
- COMP (cartilage oligomeric matrix protein), as cartilage damage and repair marker, 423-425, 434-437, 442
- Complementary and alternative medicine, advising patients concerning, 818
  - and traditional Western medicine, as best of both worlds, 830-831
  - choices of patient and, 826-827
  - consumers of, patterns of, 796-797
  - contrasted to conventional medicine, 847
  - cost of, 841-842
  - dual standard concerning, 825-826
  - evidence and clinical science questioned regarding, 849-852
  - examples of, 834
    - comments on, 834-835
  - extrapolations, projections, expenditures, and marketing considerations for, 800-801
  - growing numbers of people turning to, 824-825
  - herbal and nutritional, 835-836
  - in rheumatology, 789-968
    - epidemiology of, 789-804
  - initiation of dialogue concerning, 817-820
  - lack of randomized double-blind studies in, 827-828
  - patient responsibilities in, 829
  - patient's perspective on use of, 823-832
  - physician responsibilities in, 829-830
  - physician's perspective on, not to recommend, 833-843
    - recommending, 845-853
  - practitioners of, 840-841
  - prospective double-blind studies of, as lacking, 836-837
  - published support for use of, as lacking, 836-837
  - questions of physician concerning, 846
  - relationship between provider and client of, 848-849
  - resources on, 822
  - safety considerations for, 798-799
  - safety profile of treatments and providers of, 797-800
  - talking with patients about, 815-822
  - toxicity of, 839-840
  - use of, by health professionals, 795-796
    - by nonrheumatic disease patients, 792
    - by rheumatic disease patients, 793-795
    - population-based studies of, 790-792
  - web sites concerning, 822
  - why patients seek, 816
  - why physician and patient do not talk about, 816-817

- Compression devices, in thromboembolism prophylaxis, in joint replacement, 644-645, 649
- Compression gloves, in pain management, 239
- Computed tomography, in osteoarthritis, 452
- Conduction system disorders, preoperative risks in, 599-600
- Congestive heart failure, preoperative risks in, 596-597
- Consumerism, and quackery, 809-810
- Contraception, 539-548  
   barrier methods, 540, 542-543  
   emergency, 545-548  
   importance of, 539-540  
   intrauterine devices, 545-546  
   natural family planning, 545  
   oral, 540-541, 543  
   progestin-only, 543-546, 544  
   sterilization, 545
- Coping, assessment of, 86-87  
   in fibromyalgia, 66  
   strategies for, 220  
   training for, 222  
   in juvenile rheumatoid arthritis, 45-47
- Coping Strategies Questionnaire, 86-87
- Copper, as therapeutic agent, history of, 926  
   speculation concerning, 926, 930, 934  
   in bracelets, therapeutic benefits of, 926, 931  
   mechanism of action of, 930  
   venoms, and zinc, in treatment of rheumatoid arthritis, 919-928
- Copper salicylate, 930-931
- Coronary angioplasty, in coronary artery disease, 666  
   preoperative, 594-595
- Coronary artery bypass graft surgery, in coronary artery disease, 666  
   preoperative, 593-594
- Coronary artery disease, 657-668  
   autoimmune disease associations with, 658  
   epidemiology of, 657-658  
   evaluation of, 658-665  
     dipyridamole thallium test in, 663-664  
     functional imaging in, 661-662  
     history in, 658-661  
     in women, 664-665  
     preoperative, 588-591, 609  
     stress echocardiography in, 662-663  
     treadmill exercise test in, 661  
   hormone replacement therapy effects on, 557  
   preoperative risks in, assessment of, 588-591, 609  
     management of, 591-595  
   treatment of, 665-666
- Cortical projections, in pain transmission, 128-131
- Corticosteroids, diabetes mellitus from. See *Diabetes mellitus, corticosteroid-related*.  
   hepatotoxicity of, 751-752  
   in pregnancy, 555  
   in rheumatoid arthritis, lipid disorders from, 513  
   in systemic lupus erythematosus, lipid disorders from, 512  
   injection of, in juvenile rheumatoid arthritis, 40  
     in osteoarthritis, 19, 178  
   nephrotoxicity of, 760  
   perioperative management of, 624-626  
   pharmacokinetics of, 763  
   psoriasis exacerbation from, 757-758  
   stress doses of, 624-626  
   with phonophoresis, 909
- Cortisol, pain and, 110
- Counseling, telephone, in osteoarthritis, 225  
   in rheumatoid arthritis, 223-224
- Counterirritants, in pain management, 175, 206, 237
- COX-2. See *Cyclooxygenase-2*.
- Cranks, 808
- Crohn's disease, NSAID-related, 747-748
- Cruciate ligaments, anterior, disorders of, proprioception impairment in, 302-303, 306-307  
   reconstruction of, proprioception measurements after, 307-308
- Cryotherapy, for pain management, 235-236
- Crystal deposition disease, after joint replacement, 634
- Crystals, in osteoarthritis, 257-267  
   clinical associations of, 258-260  
   cytokine formation from, 262  
   metalloprotease induction by, 261-262  
   mitogenic effects of, 260-261  
   prevention of, 263  
   prostaglandin formation from, 262
- Cultural variables, in fibromyalgia, 70
- Cyclobenzaprine, in fibromyalgia, 172
- Cyclooxygenase-1, 361-362  
   inhibitors of, versus cyclooxygenase-2 inhibitors, 369-370
- Cyclooxygenase-2, 359-378  
   biology of, 361-362  
   discovery of, 360-361  
   genes of, 361  
   in arthritis, animal models of, 366  
     osteoarthritis, 367-368  
     rheumatoid, 366-367  
   in bone, 365  
   in central nervous system, 364-365  
   in colorectal cancer, 365-366  
   in kidney, 363-364

- in ovary, 366
- in uterus, 366
- inhibitors of, animal studies of, 362
  - clinical trials of, 370-371
  - efficacy of, 370-371
  - safety of, 371
  - selectivity of, 369-370
  - versus conventional NSAIDs, 368-369
  - versus cyclooxygenase-1 inhibitors, 369-370
- regulation of, 361-362
  - versus cyclooxygenase-1, 361-362
- Cyclooxygenase(s), isoforms of, 157, 162-163, 202
  - type 2, inhibitors of, 162-164
- Cyclophosphamide, cancer from, in
  - rheumatoid arthritis, 730
  - in pregnancy, 554
  - nephrotoxicity of, 762
  - pharmacokinetics of, 763
- Cyclosporine, hepatotoxicity of, 752-753
  - hypertension due to, 531-532
  - in pregnancy, 554
  - nephrotoxicity of, 761
  - pharmacokinetics of, 763
- Cyst(s), subchondral, in osteoarthritis, 462-463
- Cytokines, as cartilage damage and repair markers, 435, 440-441, 443
  - in osteoarthritis pathogenesis, 334-335
  - crystal-associated, 262
  - in nitric oxide release, 273
  - proinflammatory, levels of, in rheumatoid arthritis, 929
- Dapsone, in rheumatoid arthritis, 869-870
- Decoy oligonucleotides, in gene therapy, for osteoarthritis, 336-337
- Deep venous thrombosis, after joint replacement. *See* Joint replacement, thromboembolic complications of.
- Degenerative arthritis. *See* Osteoarthritis.
- Dehydroepiandrosterone, adverse effects of, 957
  - in rheumatoid arthritis, 956-957
  - in systemic lupus erythematosus, 957
- Delirium, postoperative, 613-614
- Dental procedures, endocarditis prophylaxis in, 629-631
- Depression, 687-702
  - adjustment disorder with depressed mood, 699-700
  - dysthymic disorder, 699
  - in fibromyalgia, 60, 67
  - major depressive disorder, 688-699
    - clinical features of, 689-690
    - diagnosis of, 689-691
    - differential diagnosis of, 690-691
    - suicide risk in, 691-692
    - treatment of, approach to, 692-693
      - bipolar disorder development in, 690
      - clinical course of, 698-699
      - electroconvulsive therapy in, 697-698
      - pharmacologic, 694-697
      - psychiatric consultation in, 698
      - psychotherapy in, 693-694
  - minor, 699
  - pain and, 108, 216-217
- Dermatomyositis, cancer screening in, 732-734
  - fertility in, 548
  - from statin lipid-lowering drugs, 517
  - in cancer, 764
  - pregnancy in, 552
- Desipramine, in depression, 697
  - in pain management, 174, 203
- Detsky approach, to preoperative risk assessment, 588
- Developmental variables, in fibromyalgia, 69
- Dextromethorphan, in pain management, 204
- Dextropropoxyphene, 168-170
- Diabetes mellitus, corticosteroid-related, 489-505
  - pathophysiology of, 489-491
  - prevalence of, 492
  - risk factors for, 491-492
  - treatment of, goals of, 499, 502
  - guidelines for, 498-502
  - insulin in, 497-498
  - nonpharmacologic, 493-494
  - oral glucose-lowering agents in, 494-497
  - rationale for, 492
  - severe, 502
  - strategy for, 492-493
  - hypertension in, treatment of, 524-528
  - preoperative considerations in, 611-612
- Diacylglycerol, in crystal-associated osteoarthritis, 261
- Diathermy, in pain management, 234-235
- Diclofenac, 169-170
  - adverse effects of, 906-907
  - hepatotoxicity of, 750
  - topical, clinical efficacy of, 905-906
- Diet therapy, and chronic fatigue syndrome, 951
- Dietary supplements, diet, and nutritional therapies, in rheumatic diseases, 937-968
  - in rheumatoid arthritis, 953-957
- Diet(s), anti-inflammatory or antiallergenic, in rheumatic conditions, 952-953
  - antiallergenic or anti-inflammatory, in rheumatic conditions, 952-953



## Diet(s) (Continued)

- dietary supplements, and nutritional  
 therapies, in rheumatic dis-  
 eases, 937-968  
     historical background of, 937-938  
     observations on, 939-942  
 elemental or hypoallergenic, 944-945  
 exclusion or elimination, 944  
     "fad", for arthritis, 953  
     in diabetes mellitus treatment, corticoste-  
     roid-related, 493, 502  
     in dyspepsia, 706  
     in heartburn, 709  
     in hypertension, 523-524  
     in lipid disorders, 514-515  
     in peripheral arterial disease, 678  
     osteoarthritis and. *See Vitamin(s), osteoar-  
     thritis and.*  
     vegetarian and vegan, in arthritis, 952  
     Zen macrobiotic, in rheumatic condi-  
     tions, 952  
 Diltiazem, in hypertension, in Raynaud's  
     phenomenon, 529  
 Dimethyl sulfoxide, 911-913, 914  
 Dipyridamole-thallium test, in coronary  
     artery disease, 663-664  
 Disability benefits, fibromyalgia and, 70  
 Discriminatory components, of pain,  
     functional imaging studies of, 137-138  
 Distraction, in juvenile rheumatoid  
     arthritis, 46  
 Diuretics, in hypertension, in diabetes  
     mellitus, 527-528  
 Diverticular disease, NSAID-related  
     complications of, 748  
 DNA vaccines, in immunodeficiency, 580  
 Dobutamine stress echocardiography, in  
     coronary artery disease, 662-665  
 Doxepin, in pain management, 173  
 Drugs. *See also specific drugs*  
     complications of, 745-777  
         hepatic, 748-755  
         intestinal, 745-748  
         malignant, 764-767  
         pharmacokinetics of, 763  
         postoperative delirium, 614  
         psoriasis exacerbation, 755-759  
         renal, 759-762  
         perioperative management of, 623-628  
 Duplex ultrasonography, in peripheral  
     arterial disease, 675  
 Dyadic Adjustment Scale, 94  
 Dynamic exercise, in pain management,  
     242  
 Dynamometry, of knee function, in  
     proprioception impairment, 305  
 Dyslipidemias. *See Lipid disorders.*  
 Dyspepsia, 703-708  
     causes of, 704-705  
     classification of, 703



- Evaluative components, of pain, functional imaging studies of, 138-141
- Evoked potentials, in pain imaging, 131
- Exercise, in diabetes mellitus treatment, corticosteroid-related, 493-494
- in osteoarthritis, 397-415
- benefits of, 397-398
  - comprehensive program for, 410-411
  - for cardiovascular health, 404-405, 407-408
  - for fitness, 399-400, 407-408
  - for flexibility, 401-402
  - for muscle strengthening, 290-291, 402-404
  - for proprioception enhancement, 310
  - goals of, 397-398
  - interventions for, 400
  - outcome measures for, 409-410
  - range-of-motion, 401-402
  - recommendations for, 406-408, 410
  - stress testing before, 408-409
  - therapeutic, 399
  - walking as, 405-406
- in pain management, 26, 239-244
- aerobic, 242-243
  - dynamic, 242
  - flexibility, 240-241
  - in fibromyalgia, 64
  - indications for, 239-240
  - isometric, 241-242
  - muscle conditioning, 241
  - pain assessment in, 243
  - program adoption and maintenance for, 243-244
  - range-of-motion, 240-241
  - types of, 239-240
  - with heat, 234
- in peripheral arterial disease, 678, 679
- Exercise testing, in coronary artery disease, 661
- in preoperative risk assessment, 589
- Extracellular matrix, nitric oxide effects on, 273-276
- enzyme production and activation, 275-276
  - synthesis, 274-275
- preservation of, in osteoarthritis, 335-336
- Family relationships, assessment of, 93-94
- fibromyalgia and, 69-70
- Famotidine, in dyspepsia, 708
- Fasting, and rheumatic diseases, 943-944
- Fat embolism syndrome, after joint replacement, 633-634
- Fatigue, in fibromyalgia, 56, 67
- muscle, in osteoarthritis, 289
  - proprioception impairment in, 309
- Fatty acids, dietary, and inflammatory response, 945-947
- Fecal occult blood testing, in colorectal cancer screening, 720-721
- Femoral artery, occlusive disease of, treatment of, 680-682
- Femoropopliteal occlusive disease, treatment of, 680
- Fenofibrate, in lipid disorders, 515-516
- Fertility, in rheumatic disease, 548-549
- Fetus, rheumatic disease effects on, antiphospholipid antibody syndrome, 549
- dermatomyositis, 552
  - polymyositis, 552
  - rheumatoid arthritis, 551
  - scleroderma, 552
  - systemic lupus erythematosus, 550-551
  - treatment regimens, 553-554
- Fever, after joint replacement, 634-635
- cyclooxygenase-2 inhibitors in, 364
- Fibric acid derivatives, in lipid disorders, 515-516
- Fibrin, arthritis and, 920
- Fibromuscular dysplasia, versus peripheral arterial disease, 672
- Fibromyalgia, 55-79
- clinical features of, 23-26, 55-59
  - copied strategies in, 66, 220
  - criteria for, 56
  - definition of, 55-56
  - diagnosis of, 16-17, 23-26
  - differential diagnosis of, 23-26
  - diseases coexisting with, 25-26, 56
  - pain in, biological susceptibility to, 61-65
  - cognitive-behavioral variables in, 65-68
  - environmental variables in, 68-70
  - management of, 27
  - cognitive-behavioral therapy in, 225-226
  - muscle relaxants in, 172
  - nature of, 59
  - psychological distress and, 59-61
  - psychology of, 58
  - sociocultural variables in, 68-70
  - posttraumatic, 62-64
  - reactive, 63
  - stress and, 25, 59-61, 64
- Filter, inferior vena caval, in thromboembolism prophylaxis, in joint replacement, 645
- Fish oils, for rheumatoid arthritis patients, 946
- in lipid disorders, 515-516
  - in systemic lupus erythematosus, 512
- FK-506 (tacrolimus), nephrotoxicity of, 761
- pharmacokinetics of, 763

- Flexibility exercise, in osteoarthritis, 401-402  
     in pain management, 240-241  
 Fluoxetine, in depression, 695  
     in pain management, 174-175  
 Flurbiprofen, clinical efficacy of, 906  
 Fluvastatin, in lipid disorders, 516  
 Fluvoxamine, in depression, 695  
 Food allergy, and inflammation in  
     rheumatoid arthritis, 948-950  
     in palindromic rheumatism, 951  
     in systemic lupus erythematosus, 951  
     in vasculitis, 950-951  
 Food antigens, and gastrointestinal tract, 948  
 Food sensitivities, and rheumatoid arthritis, 947-948, 949  
 Foods, and rheumatic diseases, possible relationship between, 943  
*c-fos* gene, in crystal-associated osteoarthritis, 261  
 Free radicals, oxygen. *See Oxygen radicals.*  
 Functional imaging, in coronary artery disease, 661-662  
     in pain, 123-152  
     affective-motivational components of, 138-141  
     anatomic considerations in, cortical projections, 128-131  
     subcortical, 126-128  
     brain responses in, 141-144  
     cognitive-evaluative components of, 138-141  
     pain matrix and, 131-137  
     pharmacology of, 144-146  
     psychologic integration and, 124-125  
     sensory-discriminatory components of, 137-138  
     techniques for, 131  
 Funiculi, in pain-control system, 3
- Gabapentin, in pain management, 203-204  
 Gait, impulsive joint loading during, muscle weakness and, 288  
     in osteoarthritis, proprioceptive accuracy and, 302  
 Gastroesophageal reflux disease, 708-711  
     causes of, 709  
     definition of, 708  
     epidemiology of, 708  
     hypertension in, treatment of, 529-530  
     management algorithm for, 713  
     treatment of, 709-711  
 Gastrointestinal surgery, endocarditis prophylaxis in, 629-630  
 Gastrointestinal system, NSAID effects on, 159-161, 177, 202  
     opioid effects on, 167, 201
- Gastrointestinal tract, food antigens and, 948  
 Gate control theory of pain, 1  
 Gelatinase, as cartilage damage and repair marker, 435  
     induction of, in crystal-associated osteoarthritis, 261-262  
 Gemfibrozil, in lipid disorders, 516  
 Gender, chronic pain susceptibility and, 61  
 Gene therapy, for osteoarthritis, 333-344  
     biologic principles of, 333-335  
     chondroprogenitor cells as target tissue for, 340  
     ex vivo versus in vivo, 339-340  
     products for, 336-337  
     strategies for, 335-336  
     synovium as target tissue for, 339  
     vectors for, 337-338  
     for peripheral arterial disease, 679  
     for rheumatoid arthritis, 337-338  
 General medical care, in rheumatic disease, cancer screening, 719-744  
     coronary artery disease, 657-668  
     depression, 687-702  
     diabetes mellitus, 489-505, 524-528, 611-612  
     digestive disorders, 703-718  
     drug complications, 745-777  
     hypertension, 521-537, 541, 595-596  
     large artery occlusive disease, 669-686  
     lipid disorders, 507-520  
     perioperative management, 623-638  
     preoperative risk recognition and management, 585-622  
     thromboembolic disease, 639-656  
     vaccination, 567-584  
     women's health considerations. *See Women's health issues.*  
 Genitourinary surgery, endocarditis prophylaxis in, 629-630  
 Geodes, in osteoarthritis, 462-463  
 GERI-AIMS (Geriatric Arthritis Impact Measurement Scale), 96-97  
 Ginger, in rheumatic diseases, 953-954  
 Glimepiride, in diabetes mellitus, corticosteroid-related, 494-495  
 Glipizide, in diabetes mellitus, corticosteroid-related, 494-495  
 Gloves, compression, in pain management, 239  
 Glucocorticoids, after hyaluronic acid injection, 351  
 Glucosamine, in osteoarthritis, 380-388  
     anti-inflammatory effects of, 383  
     chemistry of, 380-381  
     clinical studies of, 383-388  
     pharmacokinetics of, 381-382  
     structure-modifying properties of, 382-383  
 Glucose-lowering drugs, in diabetes mellitus, corticosteroid-related, 494-497

- Glucose tolerance, impaired, corticosteroid-related. See *Diabetes mellitus, corticosteroid-related*.
- Glyburide, in diabetes mellitus, corticosteroid-related, 494-495
- Gold therapy, functions of, 933
- in pregnancy, 554
- in rheumatoid arthritis, 933, 934
- lipid disorders in, 513
- nephrotoxicity of, 760
- pharmacokinetics of, 763
- psoriasis exacerbation from, 758
- topical, gold ring wearers and, 933-934
- Goldman approach, to preoperative risk assessment, 588
- Gout, after joint replacement, 634
- Granulocyte-macrophage colony-stimulating factor, as cartilage damage and repair marker, 443
- Granulomatosis, Wegener's, antibiotic therapy in, 872
- Gray matter, periaqueductal, in pain-control system, 2-3
- "Growing pains," 33
- Growth factors, in osteoarthritis treatment, 336
- Haemophilus influenzae* vaccination, in immunodeficiency, 571-572, 584
- Hand, rheumatoid arthritis of, pain management in, 238-239
- Healing, nitric oxide in, 276
- Health Assessment Questionnaire, 96-97
- Health hucksters, 808
- Health status measures, in pain assessment, 95-97
- Heart block, preoperative risks in, 599-600
- Heart disease. See also *Cardiovascular disease; Coronary artery disease; Myocardial infarction. atherosclerotic. See Lipid disorders*.
- Heart failure, preoperative risks in, 596-597
- Heartburn, 708-711
- causes of, 709
- definition of, 708
- epidemiology of, 708
- management algorithm for, 713
- treatment of, 709-711
- Heat, in pain management, 234-235
- Helicobacter pylori* infections, dyspepsia in, 704-708
- Helplessness, assessment of, 88-89
- learned, 219
- Heparin, discontinuation of, preoperative, 598
- in thromboembolism prophylaxis, in hip fracture repair, 648
- in joint replacement, adjusted dose, 643
- extended regime for, 651-652
- hip, 646-647
- knee, 649-650
- low molecular weight, 644, 650-651
- Hepatitis A vaccination, in immunodeficiency, 572-573, 584
- Hepatitis B, drug toxicity in, corticosteroids, 751
- cyclosporine, 752-753
- vaccination for, in immunodeficiency, 573-574, 584
- Hepatitis C, drug toxicity in, corticosteroids, 751-752
- cyclosporine, 753
- NSAIDs, 750-751
- Hepatotoxicity, of drugs. See *Liver, drug toxicity to*
- Herbs, in complementary and alternative medicine, 835-836
- Heredity, chronic pain susceptibility and, 61
- Hip, exercise for, in knee osteoarthritis, 401-402
- fracture of, thromboembolism prophylaxis in, 648-649
- osteoarthritis of, pain management in, cane for, 239
- walking exercise in, 405-406
- total replacement of, thromboembolic complications of, 646-648
- L-Histamine, in rheumatoid arthritis, 958-959
- Hodgkin's lymphoma, in rheumatoid arthritis, 729-730
- in Sjögren's syndrome, 731
- Homeopathy, as form of complementary and alternative medicine, 838-839
- Hormone replacement therapy, in menopause, 556-559
- Host defense, nitric oxide in, 276-277
- Human cartilage glycoprotein-39, as cartilage damage and repair marker, 426
- Hyaluronan, as cartilage damage and repair marker, 425, 434, 439-440, 443
- in osteoarthritis, crystal-associated, 263
- Hyaluronan binding regions, in rheumatoid arthritis, 421
- Hyaluronic acid, as cartilage damage and repair marker, 434
- intra-articular injection of, in osteoarthritis, 345-357
- anatomic considerations in, 346
- animal models of, 347-350
- arthroscopic results of, 350
- biologic effects of, 352-353
- chemical nature of, 346
- clinical trials of, 351-356

- Hyaluronic acid** (*Continued*)  
 formulations for, 348, 350-351  
 glucocorticoid therapy with, 351  
 in pharmacologic therapy failure, 345-346  
 osteophytosis in, 349  
 physical properties of, 347  
 proteoglycan synthesis in, 349-350  
 recommendations for, 355  
 repeated, 355  
 side effects of, 351  
 synovial fluid volume changes in, 352-353  
 uronic acid synthesis in, 349-350  
 versus naproxen, 353-354  
 versus NSAIDs, 353-354
- Hyaluronic acid injection**, in osteoarthritis, 178
- Hydroxychloroquine**, beneficial lipid effects of, in rheumatoid arthritis, 513  
 in systemic lupus erythematosus, 512  
 in juvenile rheumatoid arthritis, 40  
 in pregnancy, 554  
 in rheumatoid arthritis, 870
- Hydroxyl radicals**, vitamin C reaction with, 322
- Hydroxymethylglutaryl coenzyme A reductase inhibitors**, in lipid disorders, 515-517
- Hypercholesterolemia**. See *Lipid disorders*.
- Hyperglycemia**, corticosteroid-related. See *Diabetes mellitus, corticosteroid-related*.
- Hypermobility**, of knee, proprioception impairment in, 308
- Hypertension**, 521-537  
 classification of, 522-523  
 diagnosis of, 521-522  
 epidemiology of, 521  
 in drug therapy, cyclosporine, 531-532  
 oral contraceptives, 541  
 risk factors for, 522-523  
 treatment of, 521-533  
 goals of, 522  
 importance of, 521  
 in asthma, 529  
 in cyclosporine interactions, 531-532  
 in diabetes mellitus, 524-528  
 in gastroesophageal reflux disease, 529-530  
 in kidney dysfunction, 530-531  
 in peripheral arterial disease, 528  
 in Raynaud's phenomenon, 529  
 nonpharmacologic, 523-524  
 perioperative, 595-596  
 pharmacologic, 524, 531-533
- Hypertriglyceridemia**, in rheumatic disease, 514-515  
 in systemic lupus erythematosus, 512
- Hypotension**, neurally mediated, fibromyalgia and, 64-65
- Hypothalamic-pituitary-adrenal axis**, pain and, 110, 218
- Hypothalamus**, 5-6
- Ibuprofen**, absorption of, 902  
 adverse effects of, 907  
 in juvenile rheumatoid arthritis, 37-38  
 in osteoarthritis, 154-155  
 versus codeine, 168
- Imagery**, in juvenile rheumatoid arthritis, 46
- Imaging**, functional, in pain. See *Functional imaging*.
- Imipramine**, in depression, 697
- Immune response**, carotenoids in, 320  
 vitamin A in, 320  
 vitamin C in, 322-323  
 vitamin D in, 328-329  
 vitamin E in, 325
- Immunodeficiency**, vaccination in. See *Vaccination, in immunodeficiency*.
- Immunosuppressive drugs**, cancer from, in rheumatoid arthritis, 729-730  
 in systemic lupus erythematosus, 738  
 in pregnancy, 554-555  
 infertility from, 549
- Indomethacin**, in ankylosing spondylitis, 23
- Infection**, as cause of rheumatic disease, theories of, 861  
 as possible cause of rheumatoid arthritis, 863
- Inferior vena caval filter**, in thromboembolism prophylaxis, in joint replacement, 645
- Inflammation**, cyclooxygenases in, 162  
 of joints, in hyaluronic acid injection, 351  
 NSAID action against, 360  
 oxygen radicals in, 317-318  
 vitamin D and, 328
- Inflammatory bowel disease**, NSAID-related, 747-748
- Influenza vaccination**, in immunodeficiency, 577-578, 584
- Infrainguinal occlusive disease**, treatment of, 680
- Injection**, intra-articular, of hyaluronic acid. See *Hyaluronic acid, intra-articular injection of*.
- Injury**, muscle weakness after, osteoarthritis in, 288-289
- Insulin**, in diabetes mellitus, corticosteroid-related, 497-498  
 resistance to, in corticosteroid therapy, 491
- Insulin-like growth factor-1**, in crystal-associated osteoarthritis prevention, 263

- Interleukin-1 receptor antagonist, in osteoarthritis, 335-336, 338-340
- Interleukin(s), as cartilage damage and repair markers, 440-441
- formation of, in crystal-associated osteoarthritis, 262
- in cartilage catabolism, 274-275
- in osteoarthritis pathogenesis, 334-335
- Intermittent claudication, in peripheral arterial disease, 671
- Interpersonal variables, in fibromyalgia, 69-70
- Intrauterine devices, 545-546
- Intravascular ultrasonography, in peripheral arterial disease, 676
- Inventory of Negative Thoughts Related to Pain, 90-91
- Inventory of Socially Supportive Behaviors, 93
- Ionophoresis, to introduce medications transdermally, 909-910
- Iontophoresis, in pain management, 237
- Isometric exercise, in pain management, 241-242
- Japanese encephalitis vaccination, in immunodeficiency, 579
- Job satisfaction, fibromyalgia and, 70
- Joint replacement, crystal disease after, 634
- endocarditis prophylaxis after, 631
- fat embolism syndrome in, 633-634
- fever after, 634-635
- myocardial infarction after, 635
- thromboembolic complications of, 632-633, 639-656
- epidemiology of, 639
- pathophysiology of, 639-640
- prophylaxis of, 642-652
- extended, 651-652
- heparin in, 643-644, 650-651
- in hip fracture, 648-649
- in hip replacement, 646-648
- in knee replacement, 649-650
- inferior vena caval filters in, 645
- mechanical modalities in, 644-645
- warfarin in, 642-643
- risk factor classification for, 641-642
- Joint(s). See also specific joints, e.g., *Knee*.  
degenerative disease of. See *Osteoarthritis*.
- hyaluronic acid injection into. See *Hyaluronic acid, intra-articular injection* of.
- protection of, proprioception in, 301-302
- space of, magnetic resonance imaging of, in osteoarthritis, 455-457
- stability of, muscle function in, 285
- proprioception in, 301-302
- vitamin effects on. See *Vitamin(s), osteoarthritis and*.
- Juvenile rheumatoid arthritis, 31-53
- classification of, 31-32
- course of, 33-34
- epidemiology of, 31
- flares in, 34
- laboratory tests in, 32
- mood and, 34-35
- pain assessment in, 36-37
- pathophysiology of, 34
- procedural pain control in, 48-59
- psychosocial variables in, 41-42
- stress and, 34-35
- treatment of, 37-41
- cognitive-behavioral interventions in, 43-48
- versus adult rheumatoid arthritis, 35-36
- versus infectious arthritis, 32-33
- Keratan sulfate, as cartilage damage and repair marker, 419-420, 434-435, 440, 443
- Ketoprofen, absorption of, 901-902
- Ketorolac, delivered by iontophoresis, 909-910
- Kidney, cyclooxygenase-2 in, 363-364
- drug toxicity to, 759-762
- dysfunction of, hypertension in, treatment of, 530-531
- in systemic lupus erythematosus, lipid disorders in, 512
- NSAID effects on, 161-162
- Knee, anterior cruciate ligament deficiency of, proprioception impairment in, 306-307
- anterior cruciate ligament reconstruction in, proprioception impairment in, 307-308
- effusions of, hyaluronic acid injection in, 352-353
- proprioception impairment in, 308-309
- hypermobility of, proprioception impairment in, 308
- muscle fatigue of, proprioception impairment in, 309
- orthoses for, proprioception enhancement with, 309-310
- osteoarthritis of, exercise in. See *Exercise, in osteoarthritis*.
- hyaluronic acid intra-articular injections in. See *Hyaluronic acid, intra-articular injection* of.
- in vitamin D deficiency, 327
- muscle dysfunction causing, paradigm for, 291-293
- pathogenic mechanisms in, 287-290
- radiographic correlations of, 287-288
- reversal of, 290-291

Knee (*Continued*)

- sequence of events in, 286-287
- versus normal muscle function, 284-286
- proprioception impairment in, 299-314
  - age factors in, 306
  - functional effects of, 305
  - improvement of, 309-310
  - in canine cruciate-deficiency model, 303
  - knee replacement effects on, 305
  - measurement of, 302-303
  - versus nonarthritic controls, 304
  - versus normal physiology, 299-303
- radiography in, 467-480
  - field tests of, 474-476
  - in clinical trials, 476-478
  - shortcomings of, 468-471
  - standardization for, 471-474
  - treatment of, proprioception enhancement in, 309-310
- replacement of, proprioceptive accuracy in, 305
- total replacement of, thromboembolism prophylaxis in, 649-650

Lamotrigine, in pain management, 203-204

Lansoprazole, in heartburn, 710

Large artery occlusive disease. *See*

*Peripheral arterial disease.*

Laser evoked potentials, in pain imaging, 131

Laser(s), low-energy, in pain management, 237-238

Lateral pain system, 129-130

Learned helplessness, 219

Leukotrienes, formation of, in crystal-associated osteoarthritis, 262

Lifestyle modifications. *See also* *Diet*; *Exercise.*

in heartburn, 709

in peripheral arterial disease, 678

Limbic system, in pain-control system, 5

Link protein, as cartilage damage and repair marker, 435

Lipid disorders, 507-520

in psoriatic arthritis, 514

in rheumatoid arthritis, 513-514

in scleroderma, 514

in systemic lupus erythematosus, 510-513

lipid types in, 508

pathophysiology of, 508

peripheral arterial disease in, 673-674

screening for, 514

treatment of, 514-517

guidelines for, 508-509

in peripheral arterial disease, 678

nonpharmacologic, 514-515

pharmacologic, 515-517

Lipid peroxidation, in osteoarthritis, 316

vitamin C and, 322

Lipopolysaccharide, in nitric oxide

induction, 277

in prostaglandin induction, 277

Lipoproteins, disorders of. *See* *Lipid disorders.*

Liver, drug toxicity to, 748-755

azathioprine, 754-755

corticosteroids, 751-752

cyclosporine, 752-753

methotrexate, 753-754

NSAIDs, 750-751

Lovastatin, in lipid disorders, 516

Lubricin, in joint lubrication, 346

Lung cancer, in scleroderma, 735-736

Lyme arthritis, antibiotic-refractory, 873

Lyme disease, antibiotic therapy in, 873-875

chronic, alternative strategies in, 874-875

Lyme disease vaccination, in

immunodeficiency, 580

Lymphoma, in rheumatoid arthritis,

729-730

in Sjögren's syndrome, 731

in systemic lupus erythematosus, 737

McGill Pain Questionnaire, 84

Magnesium, in crystal-associated osteoarthritis, 263

Magnetic resonance imaging, functional, in pain imaging, 131, 132

affective-motivational component, 139

in osteoarthritis, 451-465

alternatives to, 451-452

artifacts in, 454

bone findings in, 461-463

cartilage findings in, 456, 458-460

in differential diagnosis, 455

joint space findings in, 455-457

location-dependent factors in, 454-455

pulse sequences for, 452-454

synovium findings in, 455-457

techniques for, 452-454

in peripheral arterial disease, 675-676

Magnetization transfer technique, in

magnetic resonance imaging, in

osteoarthritis, 454

Mammography, screening, 727

Marital adjustment to chronic pain,

assessment of, 93-94

Markers, of cartilage damage and repair,

serum, 417-432

aggrecan, 419-421

cartilage matrix protein, 425-426

- cartilage oligomeric matrix protein, 423-425
- collagen type II, 421-423
- history of, 417-418
- human cartilage glycoprotein-39, 426
- hyaluronan, 425
- keratan sulfate, 419-420
- metabolism of, 419
- minor collagens, 426
- osteonectin, 426-427
- types of, 418
- synovial fluid, 433-449
  - animal studies of, 440-442
  - clearance of, 439-440
  - concentration of, 437-439
  - longitudinal studies of, 442-444
  - types of, 434-437
- Mass hysteria, pain syndromes in, 70
- Measles-mumps-rubella vaccination, in immunodeficiency, 576, 584
- Medial pain system, 129
- Medical hydrology. *See Spa therapy.*
- Medicine, conventional, contrasted to complementary and alternative medicine, 847
- Medulla, rostralventral, in pain-control system, 3
- Meloxicam, in arthritis, 162
- Meningococcal vaccination, in immunodeficiency, 572, 584
- Menopause, 553, 556-560
  - definition of, 553
  - symptoms of, 553, 556
  - treatment of, 556-560
  - androgens in, 560
  - clonidine in, 560
  - hormone replacement therapy in, 556-559
  - propranolol in, 560
  - selective estrogen receptor modulators in, 559
- Metalloproteinases, as cartilage damage and repair markers, 435, 443
  - induction of, in crystal-associated osteoarthritis, 261-262
  - matrix, nitric oxide effects on, 275-276
- Metformin, in diabetes mellitus, corticosteroid-related, 495-497
- Methadone, withdrawal from, 198
- Methocarbamol, 171-172
- Methotrexate, cancer from, in rheumatoid arthritis, 729-730
  - hepatotoxicity of, 753-754
  - in juvenile rheumatoid arthritis, 40
  - in pregnancy, 555
  - nephrotoxicity of, 762
  - perioperative management of, 626-627
  - pharmacokinetics of, 763
- Metronidazole, in rheumatoid arthritis, 870-871
- Mexiletine, in pain management, 204-205
- Milwaukee shoulder syndrome, metalloproteinase formation in, 261-262
  - mitogenesis in, 259-260
- Mineral nutritional therapies, in rheumatic diseases, 957-959
- Mineral waters, 883, 884
- Minnesota Multiphasic Personality Inventory, in pain, 91-92
- Minocycline, in rheumatoid arthritis, 863-868
- Misoprostol, in NSAID-related ulcer prevention, 160, 202
- Mitogenesis, in crystal-associated osteoarthritis, 259-260
- Mitral valve, prolapse of, endocarditis prophylaxis in, 628, 630
  - regurgitation of, preoperative risks in, 598
  - stenosis of, preoperative risks in, 598
- MK-966, in arthritis, 164
- MK-966 (COX-2 inhibitor), in osteoarthritis, 370-371
- Monoamine oxidase inhibitors, in depression, 697
- N-Monomethyl-L-arginine, in nitric oxide inhibition, in osteoarthritis, 273-276
- Mood, in juvenile rheumatoid arthritis, pain and, 34-35
- Morphine, injection of, into joints, 171
- Motivation, pain and, functional imaging studies of, 138-141
- Motoneurons, in muscle function control, 286
- Multidimensional Pain Inventory, 94, 97-98
- Multiple sclerosis, snake venoms in, trial of, 920
- Muscle conditioning exercise, in pain management, 241
- Muscle relaxants, in pain management, 171-173, 177, 205-206
- Muscle tension, pain in, 111
- Muscle(s), dysfunction of, in osteoarthritis pathogenesis, 283-298
  - aging and, 288
  - bilateral joint damage from unilateral injury, 289
  - delayed reaction time and, 290
  - fatigue and, 289
  - gait and, 288
  - in injury, 288-289
  - paradigm for, 291-293
  - radiographic correlations of, 287-288
  - reversal of, 290-291
  - sensory dysfunction with, 290
  - sequence of events in, 286-287
  - versus normal muscle function, 284-286



Muscle(s) (*Continued*)

- fatigue of, proprioception impairment in, 309
- function of, control of, 286
- movement, 284-285
- normal, 284-286
- proprioception, 285-286
- shock absorption, 285
- stability, 285
- strengthening exercises for, in osteoarthritis, 290-291, 402-404
- Myalgia, from statin lipid-lowering drugs, 517
- c-myc* gene, in crystal-associated osteoarthritis, 261
- Myocardial infarction, after joint replacement, 635
- from oral contraceptives, 541
- preoperative risks in, assessment of, 588-591
- management of, 591-595
- Myositis, from statin lipid-lowering drugs, 517
- Nabumetone, in arthritis, 162
- Naproxen, in juvenile rheumatoid arthritis, 37-39
- in osteoarthritis, 178
- versus hyaluronic acid injection, 353-354
- National Cholesterol Education guidelines, for lipid disorder treatment, 508-509
- National Council Against Health Fraud, perspective on quackery, 805-814
- Necrosis, in peripheral arterial disease, 671
- Nefazodone, in depression, 696-697
- Negative affect. *See* Affect.
- Neonatal lupus syndrome, 551
- Nephrotoxicity, of drugs, 759-762
- Neurotensin, in pain control, 7
- Neuroticism, pain perception in, 113
- Neurotransmitters, in pain modulation, affect and, 111
- in pain perception, 195
- Neutropenia, preoperative considerations in, 609
- Neutrophil collagenase, as cartilage damage and repair marker, 435
- Niacin (nicotinic acid), in lipid disorders, 515-516
- Nifedipine, in hypertension, in Raynaud's phenomenon, 529
- "Nightshade foods", avoidance of, as anti-inflammatory measure, 952
- Nitric oxide, in osteoarthritis, 269-282
- anabolic effects of, 276-278
- catabolic effects of, 272
- cells producing, 271-272
- chondrocyte survival and, 272-273
- ex vivo studies of, 278
- extracellular matrix effects of, 273-276
- inhibition of, animal studies of, 278-279
- prostaglandins and, 277-278
- protective effects of, 276-278
- regulation in chondrocytes, 269-272
- Nitric oxide synthases, characteristics of, 270
- Nizatidine, in dyspepsia, 708
- Nociception, 105-107, 194-196
- definition of, 126
- neuroanatomy of, 126-128, 130-131
- Nonsteroidal anti-inflammatory drugs, 155-164
- absorption of, 900-902
- adverse effects of, 906-907
- analgesic action of, 202
- biological effects of, 155-158
- copper complexes of, 930-931
- cyclooxygenase-2 inhibitors, 162-164
- dyspepsia and, 705
- hepatotoxicity of, 750-751
- hypertension due to, 532-533
- in acute pain, 177
- in ankylosing spondylitis, 23
- in colorectal cancer prevention, 365-366
- in inflammatory arthritis, 159
- in juvenile rheumatoid arthritis, 37-39
- in osteoarthritis, 19, 158-159
- mechanism of action of, 360
- toxicity of, 368-369
- versus hyaluronic acid injection, 353-354
- intestinal diseases due to, 746-748
- nephrotoxicity of, 760, 762
- nonsalicylate, clinical efficacy of, 904-906
- penetration enhancement of, 902-903
- perioperative management of, 623-624
- pharmacokinetics of, 763
- psoriasis exacerbation from, 758
- side effects of, 159-162, 177
- topical, clinical efficacy of, 903-906
- cost implications of, 908
- oral ingestion of, 907
- Norepinephrine, in pain control, 6
- Nortriptyline, in pain management, 203
- NS-398 (COX-2 inhibitor), animal studies of, 362
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs.
- Nucleoside triphosphate pyrophosphohydrolase, crystal-associated osteoarthritis and, 263
- Nutraceuticals, in osteoarthritis, 379-395
- chondroitin sulfate, 387, 389-391
- collagen hydrolysate, 390, 392
- glucosamine, 380-388

- Nutrition, osteoarthritis and. See *Vitamin(s), osteoarthritis and.*
- Nutritional substitutes, in complementary and alternative medicine, 835-836
- Nutritional therapies, diet, and dietary supplements, in rheumatic diseases, 937-968
- Obesity, as surgical risk factor, 607-608
- Occlusive disease, large artery. See *Peripheral arterial disease.*
- Octacalcium phosphate crystals. See *Calcium-containing crystals.*
- Ointments, in pain management, 236-237
- Oligonucleotides, decoy, in gene therapy, for osteoarthritis, 336-337
- Omeprazole, in heartburn, 710
- in NSAID-related ulcer prevention, 161
- Opioids, 164-171
- actions of, 6-7, 164
  - addiction to, 198-200
  - adverse effects of, 167, 201-202
  - agonist, 165
  - agonist-antagonist, 165
  - antagonist, 165
  - delivery systems for, 167
  - dependence on, 167-168, 198
  - efficacy of, 168-171
  - endogenous, actions of, functional imaging of, 144-146
  - examples of, 165
  - in juvenile rheumatoid arthritis, 40-41
  - maintenance doses of, 197-198
  - monitoring log for, 199, 213
  - pseudoaddiction to, 200
  - pseudotolerance to, 200-201
  - receptors for, 164-165
  - selection of, 165, 177, 196-197
  - titration of, 197-198
  - tolerance to, 167-168, 200-201
  - treatment contract for, 199, 209-212
  - uses of, 196-197
  - withdrawal from, 167-168, 198
- Oral contraceptives, 540-541, 543
- Oral surgery, endocarditis prophylaxis in, 629-630
- Orphenadrine, 172-173
- Orthoses, in pain management, 238-239
- knee, proprioception enhancement with, 309-310
- Osteoarthritis, bone imaging in, 461-463
- clinical features of, 347
  - computed tomography in, 452
  - depression in, 216-217
  - differential diagnosis of, magnetic resonance imaging in, 455
  - exercise in, 397-415
  - for muscle strengthening, 290-291
  - for proprioception enhancement, 310
  - experimental models of, nitric oxide inhibitors in, 278-279
  - magnetic resonance imaging of, 451-465
  - markers of, serum, 417-432
  - synovial fluid, 433-449
  - of contralateral limb, 289
  - of knee. See *Knee, osteoarthritis of.*
  - of shoulder, hyaluronic acid injections in, 355
  - osteophytosis in, 349, 461-462
  - pain in, 18-20
  - assessment of, psychosocial. See *Psychosocial assessment, of pain.*
  - diagnosis of, 18-19
  - management of, 19
    - acetaminophen in, 154-155
    - antidepressants in, 174-175
    - approach to, 178-179
    - cane for, 239
    - capsaicin in, 237
    - cognitive-behavioral therapy in, 224-225
    - cold in, 235-236
    - coping strategies in, 220
    - exercise in, 239-244
    - heat in, 234-235
    - ibuprofen in, 154-155
    - low-energy lasers in, 237-238
    - NSAIDs in, 158-159
    - opioids in, 168-171
    - telephone counseling in, 225  - pathophysiology of, 18
  - versus rheumatoid arthritis, 20-21
- pathogenesis of, 333-334
- crystals in, 257-267
- cyclooxygenase-2 in, 367-368
  - muscle weakness in, 283-298
  - nitric oxide in, 269-282
  - oxygen radicals in, 316-318
  - proprioceptive impairment in, 310-311
  - prostaglandins in, 277, 367-368
  - synovial fluid viscosity reduction in, 347
- proprioceptive impairment in, 299-314
- radiography of, 451-452, 467-480
- damage correlations with, 287-288
- radionuclide imaging in, 452
- spa therapy for, 891
- treatment of, antibiotics in, 873
- exercise in, 397-415
  - for muscle strengthening, 290-291
  - for proprioception enhancement, 310
  - gene therapy for, 333-344
  - nitric oxide inhibitors in, 278-279
  - nutraceuticals in, 379-395
  - radiographic outcome measures for, 467-480
  - selective cyclooxygenase-2 inhibitors in, 359-378

- Osteoarthritis (*Continued*)  
   viscosupplementation in, 345-357  
   vitamins and, 315-332
- Osteoblasts, prostaglandins in, 365
- Osteocalcin, as cartilage damage and repair marker, 435
- Osteoclasts, prostaglandins in, 365
- Osteonectin, as cartilage damage and repair marker, 426-427
- Osteophytosis, in osteoarthritis, in hyaluronic acid injection, 349  
   magnetic resonance imaging of, 461-462
- Osteoporosis, hormone replacement therapy effects on, 557
- Oucher facial scale, in juvenile rheumatoid arthritis, 36-37
- Ovary, cyclooxygenase-2 in, 366
- Oximetry, in peripheral arterial disease, 675
- Oxycodone, in juvenile rheumatoid arthritis, 40-41
- Oxygen radicals, in joints, 271-272  
   antioxidant vitamins and, 316-318  
     vitamin A, 319-320  
     vitamin C, 322  
     vitamin E, 324-325
- Pacemaker, preoperative considerations with, 599-600
- Pain, 15-30  
   abdominal, in dyspepsia, 703  
   affective aspects of. *See Affect.*  
   animal studies of, 126-128  
   assessment of, affective aspects, 82-83  
     in exercise, 243  
     in fibromyalgia, 59  
     in pediatric patients, 36-37  
     intensity aspects, 82-83  
     psychosocial, 81-103  
   back, chronic, spa therapy for, 891-893  
   biopsychosocial model of, 82-83  
   causes of, in pediatric patients, 32-33, 34  
     in rheumatoid arthritis, 20  
   cultural variables in, 70  
   definition of, 1, 58  
   diagnosis of, 16-17  
     in ankylosing spondylitis, 22-23  
     in osteoarthritis, 18-19  
     in rheumatoid arthritis, 20-21  
     in systemic lupus erythematosus, 22  
   dimensions of, 105-107  
   functional imaging in. *See Functional imaging.*  
   in ankylosing spondylitis, 22-23  
   in fibromyalgia. *See Fibromyalgia.*  
   in osteoarthritis. *See Osteoarthritis, pain in.*  
   in pediatric patients, 31-53  
   in rheumatoid arthritis. *See Rheumatoid arthritis, pain in.*  
   in systemic lupus erythematosus, 22  
   intensity of, discrimination of, 137-138  
   laboratory studies in, 17  
   localization of, functional imaging studies of, 137-138  
   management of, 26-27  
     acute, 176-177  
     affect and, 116-117  
     aggressive pharmacologic approach to, 193-213  
     analgesics in. *See Analgesia; Nonsteroidal anti-inflammatory drugs; Opioids.*  
     chronic, analgesia in, 177-179  
     cognitive-behavioral therapy for, 43-48  
     in ankylosing spondylitis, 23  
     in fibromyalgia, 27  
     in osteoarthritis. *See Osteoarthritis.*  
     in pediatric patients, 37-41  
     in rheumatoid arthritis. *See Rheumatoid arthritis.*  
     in systemic lupus erythematosus, 22  
     inadequate, sequelae of, 194  
     patient education on, 26, 44-45, 221-222  
     pharmacology of, 195  
     physical therapy and modalities in, 233-248  
     step-wise approach to, 175-176  
   mood and, in pediatric patients, 34-35  
   musculoskeletal, without arthritis, in pediatric patients, 33  
   neuropathic, pathogenesis of, 195-196  
   neuropharmacology of, 144-146  
   neurophysiology of, clinical applications of, 23-26  
   of peripheral origin, 17-18  
   pathophysiology of, in fibromyalgia, 63  
     in juvenile rheumatoid arthritis, 34  
     in osteoarthritis, 18  
     in rheumatoid arthritis, 19-20  
   perception of, 1-13, 105-107  
     anatomic considerations in, 124-125  
     behavioral factors in, 113-114  
     circuitry involved in, 2-6  
     clinical implications of, 11  
     cognitive factors in, 112-113  
     cyclooxygenase-2 in, 364  
     environmental influences on, 11  
     gate control hypothesis of, 1  
     in fibromyalgia, 59  
     mechanisms of, 194-196  
     neurochemistry of, 6-7  
     pain matrix in, 131-137  
     pharmacology of, 194-195  
     stress and, 8-11  
     variability of, 1-2, 11

- pharmacology of, 144-146, 194-195
- procedural, in pediatric patients, 48-49
- psychology of, 58
- psychosocial factors in. *See Affect; Cognitive-behavioral therapy; Psychosocial factors.*
- quality of, discrimination of, 137-138
- sensory-discriminatory components of, functional imaging studies of, 137-138
- stress and, in pediatric patients, 34-35
- subjective experience of, 107
- suffering in, 154
- tolerance of, in fibromyalgia, 59
- sociocultural factors in, 70
- untreated, sequelae of, 194
- versus nociception, 126
- Pain behavior, affect and, 112-114
  - assessment of, 84-85
  - in fibromyalgia, 68
- Pain matrix, 131-137
- Pain threshold, in fibromyalgia, 59-60
- Papanicolaou smear, in cervical cancer screening, 724-725
- Paraffin baths, in pain management, 234
- Paroxetine, in depression, 695
- Pediatric patients, juvenile rheumatoid arthritis in, lipid disorders in, 513
  - pain in, 31-53
    - assessment of, 36-37
    - etiology of, 34
    - management of, 37-41
      - cognitive-behavioral therapy for, 43-48
    - mood and, 34-35
    - procedural, 48-49
    - psychosocial variables and, 41-42
    - stress and, 34-35
    - versus adults, 35-36
    - without arthritis, 33
- Pelotherapy, 884-885
- Penicillamine, in pregnancy, 554
  - nephrotoxicity of, 761
  - pharmacokinetics of, 763
- Pentoxifylline, in peripheral arterial disease, 679
- Peptic ulcer disease, dyspepsia in, 704
  - from NSAIDs, 159-161, 177, 202
- Periaqueductal gray matter, in pain-control system, 2-3
- Perioperative management, 623-638. *See also Preoperative considerations.*
  - autologous transfusion in, 631-632
  - endocarditis prophylaxis in, 628-631
  - in joint replacement, 632-635
  - of drugs, 623-628
  - prosthetic joint infection prevention in, 631
- Peripheral arterial disease, 669-686
  - clinical manifestations of, 671-674
  - diagnosis of, 674-677
  - differential diagnosis of, 671-672
  - hypertension in, treatment of, 528
  - incidence of, 669-670
  - morbidity and mortality in, 670
  - physical examination in, 672-673
  - risk factors for, 674
  - treatment of, 678-684
    - aortoiliac, 680
    - endovascular, 680-683
    - femoral, 680-682
    - femoropopliteal, 680
    - infrainguinal, 680
    - medical, 678-679
    - subclavian, 682-683
    - thrombolytic therapy in, 683-684
- Peroxidation, lipid, in osteoarthritis, 316
  - vitamin C and, 322
- Peroxyinitrite, production of, in joints, 271-272
- Personality factors, in pain, assessment of, 91-92
- Pharmacologic stress tests, in coronary artery disease, 662-664
- Phenelzine, in depression, 697
- Phenylbutazone, hepatotoxicity of, 750
- Phenytoin, in pain management, 203-204
- Phonophoresis, in pain management, 237
  - to introduce medications transdermally, 908-909
- Phosphocitrate, in crystal-associated osteoarthritis, 264
- Phospholipase C, activation of, in crystal-associated osteoarthritis, 261
- Photochemotherapy, systemic lupus erythematosus flares in, 759
- Physical activity, in pain management, 242-243
- Physical modalities, in pain management, 233-248
  - capsaicin, 175, 206, 237
  - cold, 235-236
  - compression gloves, 239
  - exercise, 234, 239-244
  - goals of, 233-234
  - heat, 234-235
  - iontophoresis, 237
  - low-energy lasers, 237-238
  - orthoses, 238-239
  - phonophoresis, 237
  - shoe modifications and inserts, 239
  - topical agents, 175, 206, 236-237
  - transcutaneous electrical nerve stimulation, 236
- Placebos, benefits of, 857-858, 859-860
  - history of use of, 856, 857
  - physician-patient alliance and, 858-859
- Plague vaccination, in immunodeficiency, 579
- pleasant activity scheduling, in juvenile rheumatoid arthritis, 46-47

- Pneumatic compression devices, in thromboembolism prophylaxis, in joint replacement, 644-645, 649
- Pneumococcal vaccination, in immunodeficiency, 570-571
- Polarized light microscopy, for crystal examination, in osteoarthritis, 258
- Polio vaccination, in immunodeficiency, 575-576
- Polymyositis, cancer screening in, 732-734  
fertility in, 548  
in cancer, 764  
pregnancy in, 552
- Positron emission tomography, in pain imaging, of affective-motivational components, 138-139  
of cognitive-evaluative components, 139-141  
of neuropharmacology, 144-146  
pain matrix identification in, 131-137
- Postchemotherapy rheumatism, 766-767
- Pravastatin, in lipid disorders, 516
- Prednisone, in systemic lupus erythematosus, lipid disorders from, 512
- Pregnancy, 548-553  
fertility and, 548-549  
in antiphospholipid antibody syndrome, 549-550  
in dermatomyositis, 552  
in polymyositis, 552  
in rheumatoid arthritis, 551  
in scleroderma, 551-552  
in systemic lupus erythematosus, 550-551  
rheumatic disease treatment in, 552
- Preoperative considerations, 585-622  
American Society of Anesthesiologists classification, 586  
anemia, 609, 612  
cardiovascular disease, 588-607  
arrhythmias, 599-600  
conduction disturbances, 599-600  
congestive heart failure, 596-597  
hypertension, 595-596  
ischemia, 591-595  
management algorithms for, 600-607  
risk assessment for, 588-591  
valvular, 597-599  
consultant role in, 585  
diabetes mellitus, 611-612  
elderly persons, 613-614  
pulmonary complications, 607-608  
rheumatic disease, 608-610  
risk assessment, 586  
screening tests, 585-587  
thrombocytopenia, 612-613
- Probenecid, pharmacokinetics of, 763
- Problem-solving, in juvenile rheumatoid arthritis, 47
- Professionalism, competition versus cooperation, quackery and, 810-813
- Progestin-only contraceptives, 543-546, 544
- Progressive relaxation training, in juvenile rheumatoid arthritis, 45-46
- Propoxyphene, in osteoarthritis, 179
- Proprioception, definition of, 299  
impairment of, improvement of, 309-310  
in anterior cruciate ligament deficiency, 306-307  
in anterior cruciate ligament reconstruction, 307-308  
in fatigued muscles, osteoarthritis and, 290  
in hypermobility, 308  
in knee effusions, 308-309  
in muscle fatigue, 309  
in osteoarthritis, 299-314  
age factors in, 306  
functional effects of, 305  
in canine cruciate-deficiency model, 303  
knee replacement effects on, 305  
measurement of, 302-303  
pathogenic role of, 310-311  
versus nonarthritic controls, 304  
versus normal physiology, 299-303  
measurement of, 302-303  
muscles in, 285-286  
source of, 299-301
- Prostaglandin H synthase, type 2. See *Cyclooxygenase-2*
- Prostaglandin(s), bone loss from, 162  
in bone, cyclooxygenase-2 and, 365  
in central nervous system, cyclooxygenase-2 and, 364-365  
in kidney, cyclooxygenase-2 and, 363-364  
in osteoarthritis, 367-368  
crystal-associated, 262  
nitric oxide and, 277-278  
inhibitors of, selective cyclooxygenase-2. See *Cyclooxygenase-2*, inhibitors of  
production of, mechanisms for, 360-361
- Prostate cancer, screening for, 720-724
- Prostate-specific antigen, in cancer screening, 722-723
- Prosthetic heart valves, preoperative risks with, 598
- Prosthetic joints. See *Joint replacement*
- Proteoglycans, synthesis of, in hyaluronic acid injection, 349-350
- Proto-oncogenes, in crystal-associated osteoarthritis, 261
- Pseudoaddiction, to opioids, 200
- Pseudogout, after joint replacement, 634
- Psoriasis, exacerbation of, drug-induced, 755-759
- Psoriatic arthritis, lipid disorders in, 514  
spa therapy for, 891
- Psychiatric consultation, for depression, 698

- Psychopaths, 808
- Psychosocial assessment, of pain, 81-103  
     biopsychosocial perspective and, 82-83  
     cognitive-behavioral measures in, 96-97  
     cognitive distortions in, 89-91  
     coping strategies in, 86-87  
     health status measures in, 95-96  
     helplessness in, 88-89  
     marital adjustment in, 93-94  
     pain behavior in, 84-85  
     pain measures in, 83-84  
     personality in, 91-92  
     self-efficacy concept in, 87-88  
     social support in, 92-93  
     spousal responses in, 93-94
- Psychosocial factors, in pain, 58, 215-232.  
     See also *Affect; Cognitive-behavioral therapy; Stress.*  
     anxiety, 108, 216-217  
     coping strategies, 220  
         assessment of, 86-87  
         in fibromyalgia, 66  
         training for, in juvenile rheumatoid arthritis, 45-47  
     depression, 60, 67, 108, 216-217  
     in fibromyalgia, 59-61  
     in juvenile rheumatoid arthritis, 41-42  
     in pediatric patients, 41-42  
     learned helplessness, 219  
     physiology and, 126-127  
     self-efficacy, 87-88, 219-220  
     sleep disturbances, 218
- Psychotherapy, for depression, 693-694
- Pulmonary edema, postoperative, in valvular heart disease, 598
- Pulmonary embolism, after joint replacement. See *Joint replacement, thromboembolic complications of.*
- Pulmonary function, preoperative assessment of, 607-609
- Pulse volume recording, in peripheral arterial disease, 675
- Pulses, evaluation of, in peripheral arterial disease, 673
- Quackery, changed attitudes toward, 807-808  
     changing terminology masking, 806-807  
     components of, 805  
     definition of, 806  
     perspective of National Council Against Health Fraud on, 805-814  
     size of problem of, 807-808  
     use of, versus promotion of false practices in, 806
- Quack(s), definition of, 806
- kinds of, 808-809
- Quadriceps dysfunction, in osteoarthritis  
     pathogenesis, mechanisms of, 287-290  
     paradigm for, 291-293  
     reversal of, 290-291
- Quinacrine, psoriasis exacerbation from, 756-757
- Rabies vaccination, in immunodeficiency, 579-580, 584
- Radiography, in osteoarthritis, 451-452  
     as outcome measure, 467-480  
     disease progression descriptions in, 471  
     field tests of, 474-476  
     in clinical trials, 476-478  
     knee flexion position for, 468-469  
     magnification for, 470  
     shortcomings of, 468-471  
     standardization for, 471-474  
     x-ray beam alignment for, 469  
     crystal-associated, 258-259  
     damage correlations with, 287-288
- Radiolabeled albumin (RISA), in synovial space measurement, 439-441, 443-444
- Radionuclide imaging, in osteoarthritis, 452
- Raloxifene, in menopause, 559
- Range-of-motion exercise, in osteoarthritis, 401-402  
     in pain management, 240-241
- Ranitidine, in dyspepsia, 708  
     in heartburn, 710
- Raynaud's phenomenon, hypertension in, treatment of, 529
- Reaction time, delayed, in osteoarthritis, 290
- Reactive arthritis, in influenza vaccination, 577
- Reactive oxygen species. See *Oxygen radicals.*
- Relapse prevention training, 222-223
- Relaxation training, in juvenile rheumatoid arthritis, 45-46
- Repaglinide, in diabetes mellitus, corticosteroid-related, 494-496
- Reproduction tests, for knee proprioception, 303
- Respiratory depression, from opioids, 167, 201-202
- Respiratory system, preoperative assessment of, 607-609
- Rest pain, in peripheral arterial disease, 672
- Retinol (vitamin A), osteoarthritis and, 318-321  
     in bone development, 321

- Retinol (vitamin A) (*Continued*)  
 in cell differentiation, 320  
 in immune response, 320  
 in oxidative stress, 319-320
- Rheumatic disease, antibiotics for treatment of, 861-881
- diet, dietary supplements, and nutritional therapies in, 937-968
- infectious causes of, theories of, 861
- pathogenesis of, immune or inflammatory mechanisms in, antimicrobials and, 875-877
- spa therapy in, 883-897
- topical agents in treatment of, 899-918
- trace elements in treatment of, 929-935
- Rheumatism, palindromic, food allergy in, 951
- Rheumatoid arthritis, cancer screening in, 728-732
- cartilage damage and repair markers in, 444
- cause of, possibility of infection as, 863
- ceftriaxone in, 870
- cyclooxygenase-2 in, 366-367
- dapsone in, 869-870
- diet supplements in, 953-957
- disability in, 126
- fertility in, 548
- food sensitivities and, 947-948, 949
- gene therapy for, 337-338
- hyaluronan binding regions in, 421
- hydroxychloroquine in, 870
- in menopause, 558, 560
- inflammation in, food allergy and, 948-950
- intra-articular rifamycin in, 869
- juvenile. *See Juvenile rheumatoid arthritis.*
- lipid disorders in, 513-514
- metronidazole in, 870-871
- minocycline in, 863-868
- nitric oxide production in, 278
- oral contraceptives in, 541
- pain in, 19-21
- affect and, physiologic mechanisms in, 110-112
- psychological mechanisms in, 112-114
- assessment of. *See Psychosocial assessment, of pain.*
- brain responses in, 141-144
- causes of, 20
- depression and, 108, 216-217
- diagnosis of, 20-21
- functional imaging in, 145-146
- management of, 21
- antidepressants in, 174-175
- capsaicin in, 237
- cognitive-behavioral therapy in, 223-224
- cold in, 235-236
- compression gloves in, 239
- coping strategies for, 220
- exercise in, 239-244
- heat in, 234-235
- low-energy lasers in, 237-238
- NSAIDs in, 159
- orthoses in, 238-239
- shoe modifications in, 239
- telephone counseling in, 223-224
- transcutaneous electrical nerve stimulation in, 236
- pathophysiology of, 19-20
- versus osteoarthritis pain, 20-21
- pregnancy in, 551
- preoperative considerations in, 610
- spa therapy for, 889, 890
- sulfasalazine in, 868-869
- vaccination in, influenza, 578
- tetanus-diphtheria toxoid, 569
- venoms, copper, and zinc in treatment of, 919-928
- Rheumatology, complementary and alternative practices in. *See Complementary and alternative medicine.*
- Rheumatology Attitudes Index, 89
- Rifamycin, intra-articular, in rheumatoid arthritis, 869
- Sacroiliitis, in ankylosing spondylitis, 22-23
- Salicylates, absorption of, 900-902
- clinical efficacy of, 903-904
- penetration enhancement of, 902-903
- SC-58125 (COX-2 inhibitor), animal studies of, 362
- Schuss view, in knee radiography, 471-473
- Scleroderma, cancer screening in, 734-736
- fertility in, 548
- heartburn in, treatment of, 711
- lipid disorders in, 514
- pregnancy in, 551-552
- Sclerosis, subchondral, in osteoarthritis, 461
- Selective estrogen receptor modulators, in menopause, 559
- Selective serotonin reuptake inhibitors, in depression, 695-696
- in pain management, 174-175, 203
- Selenium, in rheumatoid arthritis, 931-932
- properties of, 931
- therapeutic benefits of, 932
- Self-efficacy concept, in chronic pain, 219-220
- assessment of, 87-88
- Sensory-discriminatory components, of pain, functional imaging studies of, 137-138
- Sensory dysfunction, in osteoarthritis, 290.
- See also Proprioception, impairment of.*



- Serotonin, in pain control, 6
- Sertraline, in depression, 695
- Serum markers, of cartilage damage and repair. *See Markers, of cartilage damage and repair.*
- Sex hormones, pain and, 110-111
- Shark cartilage, in chronic disease, 955-956
- Shock absorption, muscles in, 285
- Shoe modifications and inserts, in pain management, 239
- Shoes, walking, in osteoarthritis, 405-406
- Short-wave diathermy, in pain management, 235
- Shoulder, Milwaukee, metalloproteinase formation in, 261-262
- mitogenesis in, 259-260
- osteoarthritis of, hyaluronic acid injections in, 355
- Sialoprotein, bone, as cartilage damage and repair marker, 435
- Sickness Impact Profile, in pain, 95, 97
- Sigmoidoscopy, in colorectal cancer screening, 721
- Simvastatin, in lipid disorders, 516
- Single-photon emission computed tomography, in pain imaging, 131
- Sjögren's syndrome, cancer screening in, 730-731
- SLE. *See Systemic lupus erythematosus.*
- Sleep, in fibromyalgia, 62, 218
- in juvenile rheumatoid arthritis, 41
- in osteoarthritis, 218
- in rheumatoid arthritis, 218
- Small intestine, nonsteroidal anti-inflammatory drug toxicity to, 746-747
- Smoking cessation, in peripheral arterial disease, 678
- preoperative, 607
- Snake venoms, healing qualities of, Greek healers and, 921-922
- historical review of, 919-920
- in arthritis, and in multiple sclerosis, trial of, 920
- studies of, 920-921
- medications based on, banning of, 920
- Social support, assessment of, 92-93
- Social Support Questionnaire, 93
- Sociocultural variables, in fibromyalgia, 68-70
- Somatic complaints, in fibromyalgia, 56-57
- Spa therapy, adverse effects of, 893
- chemical effects of, 887-888
- clinical studies of, 888-893
- contraindications to, 893-894
- for ankylosing spondylitis, 889-891
- for chronic back pain, 891-893
- for osteoarthritis, 891
- for psoriatic arthritis, 891
- for rheumatoid arthritis, 889, 890
- history of, 886-887
- in rheumatic disease, 883-897
- mechanical effects of, 885-886
- mechanisms of action of, 885-888
- therapeutic modalities associated with, 883-884
- thermal effects of, 886-887
- types and nomenclature of therapies in, 884
- SPARC (osteonectin), as cartilage damage and repair marker, 426-427
- Spine, osteoarthritis of, walking exercise in, 405-406
- Spino-reticulothalamic tracts, in pain transmission, 128
- Spinothalamic tract, in pain transmission, 126-128, 130
- Spondyloarthropathies, seronegative, antibiotic therapy in, 871-872
- NSAIDs in, 159
- Spousal response to chronic pain, assessment of, 93-94
- Statins, in lipid disorders, 515-517
- Stents, in peripheral arterial disease, 680-681, 683
- Stiffness, in osteoarthritis, 18
- Stomach, cancer of, versus dyspepsia, 706-707
- Streptokinase, in peripheral arterial disease, 684
- Stress, analgesia induced by, 8-9
- fibromyalgia and, 25, 59-61, 64
- in juvenile rheumatoid arthritis, pain and, 34-35
- in rheumatoid arthritis, pain and, 110-112, 217-218
- interactions with pain pathway, 8-11
- oxidative. *See Oxygen radicals.*
- perioperative, corticosteroid doses for, 624-626
- Stress testing, exercise, in osteoarthritis, 408-409
- in coronary artery disease, 661-662
- in preoperative risk assessment, 589, 590
- Stroke, from oral contraceptives, 541
- Stromelysin, as cartilage damage and repair marker, 435, 442
- in aggrecan cleavage, 421
- induction of, in crystal-associated osteoarthritis, 261-262
- Stroop task, brain areas activated in, 139-140
- Subchondral cysts, in osteoarthritis, 462-463
- Subchondral sclerosis, in osteoarthritis, 461
- Subclavian artery, occlusive disease of, treatment of, 682-683
- Suicide risk, in depression, 691-692
- Sulfasalazine, in juvenile rheumatoid arthritis, 40
- in rheumatoid arthritis, 868-869

- Sulfasalazine (*Continued*)  
 in seronegative spondyloarthropathies, 872  
 pharmacokinetics of, 763
- Sulfonylureas, in diabetes mellitus, corticosteroid-related, 494-495
- Sulindac, hepatotoxicity of, 750
- Superoxide anion, production of, in joints, 271-272  
 vitamin C reaction with, 322
- Supraventricular arrhythmias, preoperative risks in, 599
- Suprofen, in osteoarthritis, 169
- Surgery, perioperative considerations for.  
 See *Perioperative management*;  
*Preoperative considerations*.
- Sympathetic adrenal-medullary system, pain and, 111, 218
- Synovial fluid, cartilage damage and repair markers in. See *Markers, of cartilage damage and repair*.  
 examination of, in crystal-associated osteoarthritis, 258-260  
 physical characteristics of, 347  
 viscosupplementation of, with hyaluronic acid. See *Hyaluronic acid, intra-articular injection of*.  
 vitamin D metabolites in, 327-328  
 volume changes in, after hyaluronic acid injection, 352-353
- Synovium, as gene therapy target, in osteoarthritis, 339  
 magnetic resonance imaging of, in osteoarthritis, 455-457  
 pathology of, in osteoarthritis, 333-334  
 proliferation of, in crystal-associated arthritis, 259-260
- Systemic lupus erythematosus, cancer screening in, 736-739  
 contraception in, 541, 546  
 coronary artery disease in, 658  
 dehydroepiandrosterone in, 957  
 eicosapentaenoic acid in, 947  
 fertility in, 548  
 food allergy in, 951  
 in menopause, 558-559  
 lipid disorders in, 510-513  
 pain in, 22  
 pregnancy in, 550-551  
 preoperative considerations in, 610  
 psoriasis with, treatment conflicts in, 759  
 vaccination in, influenza, 577-578  
 pneumococcal, 570-571
- Systemic sclerosis. See *Scleroderma*.
- Tacrolimus (FK-506), nephrotoxicity of, 761  
 pharmacokinetics of, 763
- Takayasu's arteritis, versus peripheral arterial disease, 672, 676
- Tamoxifen, in menopause, 559
- Telephone counseling, in osteoarthritis, 225  
 in rheumatoid arthritis, 223-224
- Tender points, examination of, 17, 25  
 reduced pain threshold at, 59  
 sites for, 21  
 versus psychological distress level, 60
- TENS (transcutaneous electrical nerve stimulation), in pain management, 236
- Testosterone, in menopause, 560
- Tetanus-diphtheria toxoid vaccination, in immunodeficiency, 569-570, 584
- Thalamic nuclei, in pain transmission, 127-128  
 projections of, 128-131
- Thermal therapy. See *Spa therapy*.
- Thermometer, pain, in juvenile rheumatoid arthritis, 37
- Thiazolidinediones, in diabetes mellitus, corticosteroid-related, 495, 497
- Threshold tests, for knee proprioception, 302-303
- Thrombocytopenia, preoperative considerations in, 609, 612-613
- Thromboembolic disorders, after joint replacement. See *Joint replacement, thromboembolic complications of*.  
 in antiphospholipid antibody syndrome, pregnancy and, 549-550
- Thrombolytic therapy, for peripheral arterial disease, 683-684
- Tiagabine, in pain management, 203-204
- Ticlopidine, in peripheral arterial disease, 678
- Tissue inhibitor of metalloproteinase (TIMP), as cartilage damage and repair marker, 435, 442, 443
- Tissue plasminogen activator, in peripheral arterial disease, 684
- Tizanidine, in pain management, 205
- Tocopherols, osteoarthritis and, 323-325
- Tolmetin, in juvenile rheumatoid arthritis, 37-38
- Topical agents, in treatment of rheumatic disorders, 899-918  
 examples of, 900  
 physical modalities to improve effectiveness of, 908-910  
 rationale for, 899-900
- Topical applications, in pain management, 175, 206, 236-237
- Topiramate, in pain management, 203-204
- Trace elements, in musculoskeletal disorders, historical review of, 929  
 in treatment of rheumatic conditions, 929-935  
 spa therapy and, 887-888
- Tramadol, 165-168, 170

- dose for, 197  
 in osteoarthritis, 179
- Transcutaneous electrical nerve stimulation, in pain management, 236
- Transforming growth factor- $\beta$ , in osteoarthritis treatment, 336, 339-340  
 inhibition of, in crystal-associated osteoarthritis prevention, 263
- Transfusions, autologous, for surgery, 631-632
- Transplantation, of chondrocytes, in osteoarthritis, 336
- Tranylcypromine, in depression, 697
- Trauma, as fibromyalgia trigger, 62-64
- Travel, vaccines recommended for, in immunodeficiency, 568, 578-580
- Trazodone, in pain management, 174
- Treadmill test, in coronary artery disease, 661
- Triamcinolone, injection of, in osteoarthritis, 178
- Tricalcium phosphate crystals. *See* *Calcium-containing crystals.*
- Tricyclic antidepressants, in depression, 697
- Troglitazone, in diabetes mellitus, corticosteroid-related, 495, 497
- Tumor necrosis factor- $\alpha$ , as cartilage damage and repair marker, 440-441  
 in osteoarthritis pathogenesis, 334-335
- Typhoid vaccination, in immunodeficiency, 579
- Ulcerative colitis, NSAID-related, 747-748
- Ulcers, gastric, from NSAIDs, 159-161, 177, 202  
 in peripheral arterial disease, 672
- Ultrasonography, in peripheral arterial disease, Duplex, 675  
 intravascular, 676
- Ultrasound, in pain management, 234-235  
 in phonophoresis, 237
- Urokinase, in peripheral arterial disease, 684
- Uronic acid, synthesis of, in hyaluronic acid injection, 349-350
- Uterus, cyclooxygenase-2 in, 366
- Vaccination, in immunodeficiency, 567-584  
 anthrax, 579  
 bacille-Calmette-Guerin, 579  
 for international travel, 568, 578-580  
*Haemophilus influenzae*, 571-572, 584  
 hepatitis A, 572-573, 584  
 hepatitis B, 573-574, 584  
 influenza, 577-578, 584  
 Japanese encephalitis, 579  
 measles-mumps-rubella, 576, 584  
 meningococcal, 572, 584  
 new products for, 580  
 plague, 579  
 pneumococcal, 570-571  
 polio, 575-576  
 rabies, 579-580, 584  
 recommended, 568  
 tetanus-diphtheria toxoid, 569-570, 584  
 typhoid, 579  
 vaccines not recommended, 568  
 varicella, 574-575, 584  
 yellow fever, 579
- Valvular heart disease, preoperative risks in, 597-599
- Varicella vaccination, in immunodeficiency, 574-575, 584
- Varni-Thompson Pediatric Pain Questionnaire, in juvenile rheumatoid arthritis, 36-37
- Vascular endothelial cell growth factor, in peripheral arterial disease, 679
- Vasculitis, food allergy in, 950-951  
 versus peripheral arterial disease, 676
- Vegetarian and vegan diets, in arthritis, 952
- Vena cava, inferior, filter in, for thromboembolism prophylaxis, in joint replacement, 645
- Venlafaxine, in depression, 696
- Venoms, copper, and zinc, in treatment of rheumatoid arthritis, 919-928
- Venous thrombosis, after joint replacement. *See* *Joint replacement, thromboembolic complications of.*
- Ventricular arrhythmias, preoperative risks in, 599
- Verbal rating scales, in pain assessment, 82-83
- Viruses, as gene therapy vectors, 337-338
- Viscosupplementation, with hyaluronic acid. *See* *Hyaluronic acid, intra-articular injection of.*
- Visual analog scales, in pain assessment, 82-83  
 in juvenile rheumatoid arthritis, 36-37
- Visual analogue tests, for knee proprioception, 303
- Vitamin A, osteoarthritis and, 318-321  
 in bone development, 321  
 in cell differentiation, 320  
 in immune response, 320  
 in oxidative stress, 319-320
- Vitamin C, osteoarthritis and, 321-323
- Vitamin D, osteoarthritis and, 326-329  
 chemistry of, 326  
 in bone metabolism, 328-329  
 in cell differentiation, 328-329

- Vitamin D (*Continued*)  
     in immune response, 328-329  
 Vitamin E, osteoarthritis and, 323-325  
 Vitamin therapies, in rheumatic diseases, 957-959  
 Vitamin(s), osteoarthritis and, 315-332  
     antioxidant effects of, 316-318  
     vitamin A, 318-321  
     vitamin C, 321-323  
     vitamin D, 326-329  
     vitamin E, 323-325
- Walking, for exercise, in osteoarthritis, 405-406  
 Warfarin, discontinuation of, preoperative, 598  
     in thromboembolism prophylaxis, in  
       joint replacement, 642-643  
       hip, 647-648  
       knee, 649-650  
 Water, hypothermal, 884  
     mineral, 883, 884  
 Ways of Coping scale, 86  
 Weakness, muscular. *See Muscle(s), dysfunction of.*  
 Wegener's granulomatosis, antibiotic therapy in, 872  
 Weight reduction, in hypertension, 523-524  
 Whiplash injury, fibromyalgia and, 63-64  
 Women's health issues, 539-565  
     cancer screening, breast, 725-727  
     cervical, 724-725  
     contraception, 539-548  
     coronary artery disease, 664-665  
     menopause, 553, 556-560  
     pregnancy, 548-555  
 Work environment, fibromyalgia and, 70  
 Workers' compensation, fibromyalgia and, 70
- Xanthomas, in peripheral arterial disease, 673-674
- Yellow fever vaccination, in immunodeficiency, 579
- Zen macrobiotic diet, in rheumatic conditions, 952  
 Zinc, in rheumatic arthritis, 926, 932-933  
     venoms, and copper, in treatment of rheumatoid arthritis, 919-928

